Form 4: AN2 Therapeutics Director Acquires Shares
Insider Transaction Report
Patricia A. Martin, a Director at AN2 Therapeutics, Inc., acquired 1,192 shares of common stock on April 10, 2026, as part of her compensation.
Summary
- Patricia A. Martin, a Director at AN2 Therapeutics, Inc., acquired 1,192 shares of common stock on April 10, 2026.
- These shares were issued in lieu of cash compensation under the company's non-employee director compensation policy.
- All acquired shares vest immediately.
- Following this transaction, Ms. Martin beneficially owns 18,097 shares of common stock directly.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard compensation-related stock acquisition by a director and does not contain new financial performance data or strategic shifts.
Positives
- Director compensation policy is in place, indicating a structured approach to incentivizing board members.
- Immediate vesting of shares suggests confidence in the company's value or a standard practice for director compensation.
- Acquisition of shares by a director can be interpreted as a positive signal of commitment to the company.
Future Outlook
No specific future outlook or guidance is provided in this filing.
Industry Context
StockSavvy.ai notes that Form 4 filings are standard for reporting insider transactions, including those related to director compensation, and are a routine part of corporate governance disclosure in the biotechnology sector.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Director Compensation Policy | Shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy. | Not specified, but transaction occurred on 04/10/2026 | Standard practice for director compensation, ensures alignment of director interests with shareholders. |
Related Party Transactions
- Acquisition of 1,192 shares of common stock by Director Patricia A. Martin in lieu of cash compensation.
Stakeholder Impact
- Shareholders: The issuance of shares dilutes existing ownership slightly, but aligns director incentives with shareholder value.
- Employees: No direct impact mentioned.
- Management: No direct impact mentioned.
- Creditors: No direct impact mentioned.
Key Dates
| Date | Description |
|---|---|
| 04/10/2026 | Earliest transaction date and date of stock acquisition. |
Keywords
AN2 Therapeutics, ANTX, Form 4, Director Compensation, Stock Acquisition, Beneficial Ownership, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.